

**RECEIVED**  
**CENTRAL FAX CENTER**

Application No.  
Reply to Office Action of10/595,807 Amendment Dated  
December 31, 2008

June 1, 2009


JUN 01 2009

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A compound of formula (I):



wherein:

**A** is a direct bond or  $C_{1-2}$ alkylene; wherein said  $C_{1-2}$ alkylene may be optionally substituted by one or more  $R^{22}$ ;

**Ring C** is carbocycll or heterocycll;

**R<sup>1</sup>** and **R<sup>4</sup>** are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkanoyl,  $C_{1-6}$ alkanoyloxy,  $N-(C_{1-6}$ alkyl)amino,  $N,N-(C_{1-6}$ alkyl)<sub>2</sub>amino,  $C_{1-6}$ alkanoylamino,  $N-(C_{1-6}$ alkyl)carbamoyl,  $N,N-(C_{1-6}$ alkyl)<sub>2</sub>carbamoyl,  $C_{1-6}$ alkylS(O)<sub>a</sub> wherein a is 0 to 2,  $C_{1-6}$ alkoxycarbonyl,  $N-(C_{1-6}$ alkyl)sulphamoyl,  $N,N-(C_{1-6}$ alkyl)<sub>2</sub>sulphamoyl,  $C_{1-6}$ alkylsulphonylamino, carbocycll or heterocycll; wherein  $R^1$  and  $R^4$  independently of each other may be optionally substituted on carbon by one or more  $R^8$ ; and wherein if said heterocycll contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from  $R^9$ ;

**R<sup>2</sup>** is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkanoyl,  $C_{1-6}$ alkanoyloxy,  $N-(C_{1-6}$ alkyl)amino,  $N,N-(C_{1-6}$ alkyl)<sub>2</sub>amino,  $C_{1-6}$ alkanoylamino,  $N-(C_{1-6}$ alkyl)carbamoyl,  $N,N-(C_{1-6}$ alkyl)<sub>2</sub>carbamoyl,  $C_{1-6}$ alkylS(O)<sub>a</sub> wherein a is 0 to 2,  $C_{1-6}$ alkoxycarbonyl,  $N-(C_{1-6}$ alkyl)sulphamoyl,  $N,N-(C_{1-6}$ alkyl)<sub>2</sub>sulphamoyl,

Application No.  
Reply to Office Action of

10/595,807 Amendment Dated  
December 31, 2008

June 1, 2009

C<sub>1-6</sub>alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R<sup>2</sup> may be optionally substituted on carbon by one or more R<sup>10</sup>; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R<sup>11</sup>;

R<sup>3</sup> is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkanoyloxy, N-(C<sub>1-6</sub>alkyl)amino, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, C<sub>1-6</sub>alkanoylamino, N-(C<sub>1-6</sub>alkyl)carbamoyl, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>1-6</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-6</sub>alkoxycarbonyl, N-(C<sub>1-6</sub>alkyl)sulphamoyl, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>sulphamoyl, C<sub>1-6</sub>alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R<sup>3</sup> may be optionally substituted on carbon by one or more R<sup>12</sup>; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R<sup>13</sup>;

R<sup>6</sup> is hydrogen or optionally substituted C<sub>1-6</sub>alkyl; wherein said optional substituents are selected from one or more R<sup>14</sup>;

R<sup>6</sup> and R<sup>7</sup> are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkanoyloxy, N-(C<sub>1-6</sub>alkyl)amino, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, C<sub>1-6</sub>alkanoylamino, N-(C<sub>1-6</sub>alkyl)carbamoyl, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>1-6</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-6</sub>alkoxycarbonyl, N-(C<sub>1-6</sub>alkyl)sulphamoyl, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>sulphamoyl, C<sub>1-6</sub>alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R<sup>6</sup> and R<sup>7</sup> independently of each other may be optionally substituted on carbon by one or more R<sup>15</sup>; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R<sup>16</sup>;

or R<sup>6</sup> and R<sup>7</sup> together with the pyrimidine bond to which they are attached form a 5 or 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R<sup>17</sup>; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R<sup>18</sup>;

n = 0, 1, 2 or 3; wherein the values of R<sup>3</sup> may be the same or different;

R<sup>8</sup>, R<sup>10</sup>, R<sup>12</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>17</sup> and R<sup>22</sup> are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkanoyloxy, N-(C<sub>1-6</sub>alkyl)amino, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, C<sub>1-6</sub>alkanoylamino, N-(C<sub>1-6</sub>alkyl)carbamoyl, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl,

Application No.  
Reply to Office Action of

10/595,807 Amendment Dated  
December 31, 2008

June 1, 2009

$C_{1-6}alkylS(O)_a$  wherein a is 0 to 2,  $C_{1-6}alkoxycarbonyl$ ,  $N-(C_{1-6}alkyl)sulphamoyl$ ,  $N,N-(C_{1-6}alkyl)_2sulphamoyl$ ,  $C_{1-6}alkylsulphonylamino$ , carbocyclyl or heterocyclyl; wherein  $R^8$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{14}$ ,  $R^{16}$ ,  $R^{17}$  and  $R^{22}$  independently of each other may be optionally substituted on carbon by one or more  $R^{18}$ ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from  $R^{20}$ ;

$R^9$ ,  $R^{11}$ ,  $R^{13}$ ,  $R^{16}$ ,  $R^{18}$  and  $R^{20}$  are independently selected from  $C_{1-6}alkyl$ ,  $C_{1-6}alkanoyl$ ,  $C_{1-6}alkylsulphonyl$ ,  $C_{1-6}alkoxycarbonyl$ , carbamoyl,  $N-(C_{1-6}alkyl)carbamoyl$ ,  $N,N-(C_{1-6}alkyl)carbamoyl$ , benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein  $R^9$ ,  $R^{11}$ ,  $R^{13}$ ,  $R^{16}$ ,  $R^{18}$  and  $R^{20}$  independently of each other may be optionally substituted on carbon by one or more  $R^{21}$ ;

$R^{19}$  and  $R^{21}$  are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl,  $C_{1-6}alkyl$ ,  $C_{2-6}alkenyl$ ,  $C_{2-6}alkynyl$ ,  $C_{1-6}alkoxy$ ,  $C_{1-6}alkanoyl$ ,  $C_{1-6}alkanoyloxy$ ,  $N-(C_{1-6}alkyl)amino$ ,  $N,N-(C_{1-6}alkyl)_2amino$ ,  $C_{1-6}alkanoylamino$ ,  $N-(C_{1-6}alkyl)carbamoyl$ ,  $N,N-(C_{1-6}alkyl)_2carbamoyl$ ,  $C_{1-6}alkylS(O)_a$  wherein a is 0 to 2,  $C_{1-6}alkoxycarbonyl$ ,  $N-(C_{1-6}alkyl)sulphamoyl$ ,  $N,N-(C_{1-6}alkyl)_2sulphamoyl$ ,  $C_{1-6}alkylsulphonylamino$ , carbocyclyl or heterocyclyl; wherein  $R^{19}$  and  $R^{21}$  independently of each other may be optionally substituted on carbon by one or more  $R^{23}$ ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from  $R^{24}$ ;

$R^{23}$  is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino,  $N$ -methyl- $N$ -ethylamino, acetylamino,  $N$ -methylcarbamoyl,  $N$ -ethylcarbamoyl,  $N,N$ -dimethylcarbamoyl,  $N,N$ -diethylcarbamoyl,  $N$ -methyl- $N$ -ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl,  $N$ -methylsulphamoyl,  $N$ -ethylsulphamoyl,  $N,N$ -dimethylsulphamoyl,  $N,N$ -diethylsulphamoyl or  $N$ -methyl- $N$ -ethylsulphamoyl; and

$R^{24}$  is selected from  $C_{1-6}alkyl$ ,  $C_{1-6}alkanoyl$ ,  $C_{1-6}alkylsulphonyl$ ,  $C_{1-6}alkoxycarbonyl$ , carbamoyl,  $N-(C_{1-6}alkyl)carbamoyl$ ,  $N,N-(C_{1-6}alkyl)_2carbamoyl$ , benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not:

5-bromo- $N^4$ -(5-methyl-1H-pyrazol-3-yl)- $N^2$ -[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-chloro- $N^4$ -(5-methyl-1H-pyrazol-3-yl)- $N^2$ -[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-bromo- $N^2$ -[1-(3-methyl-5-isoxazolyl)ethyl]- $N^4$ -(5-methyl-1H-pyrazol-3-yl)-2,4-

Application No.  
Reply to Office Action of

10/595,807Amendment Dated  
December 31, 2008

June 1, 2009

pyrimidinediamine;

5-chloro-N<sup>2</sup>-[1-(3-methyl-5-isoxazolyl)ethyl]-N<sup>4</sup>-(5-methyl-1H-pyrazol-3-yl)-2,4-pyrimidinediamine;  
5-bromo-N<sup>4</sup>-(5-methyl-1H-pyrazol-3-yl)-N<sup>2</sup>-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;  
5-chloro-N<sup>4</sup>-(5-methyl-1H-pyrazol-3-yl)-N<sup>2</sup>-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;  
5-chloro-N<sup>4</sup>-(5-methyl-1H-pyrazol-3-yl)-N<sup>2</sup>-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine;  
5-bromo-N<sup>4</sup>-(5-methyl-1H-pyrazol-3-yl)-N<sup>2</sup>-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine; or  
5-bromo-N<sup>4</sup>-(5-methyl-1H-pyrazol-3-yl)-N<sup>2</sup>-[1-(2-pyridinyl)ethyl]-2,4-pyrimidinediamine.

2. (original) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein A is a direct bond.

3. (previously presented) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein Ring C is phenyl, thienyl, pyridyl, thiazolyl.

4. (previously presented) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R<sup>1</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, C<sub>1-6</sub>alkylS(O)<sub>a</sub> wherein a is 0 or carbocyclyl; wherein R<sup>1</sup> may be optionally substituted on carbon by one or more R<sup>8</sup>; wherein R<sup>8</sup> is selected from halo or carbocyclyl.

5. (previously presented) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R<sup>4</sup> is hydrogen.

6. (previously presented) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein:

R<sup>2</sup> is selected from C<sub>1-6</sub>alkyl; wherein R<sup>2</sup> may be optionally substituted on carbon by one or more R<sup>10</sup>;

R<sup>10</sup> is selected from halo hydroxy, carboxy, amino, C<sub>1-6</sub>alkoxy, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, C<sub>1-6</sub>alkanoylamino, N-(C<sub>1-6</sub>alkyl)carbamoyl, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl or heterocyclyl; wherein R<sup>10</sup> may be optionally substituted on carbon by one or more R<sup>19</sup>; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R<sup>20</sup>;

R<sup>19</sup> is selected from hydroxy or C<sub>1-6</sub>alkoxy;

R<sup>20</sup> is selected from C<sub>1-6</sub>alkyl.

Application No.  
Reply to Office Action of

10/595,807 Amendment Dated  
December 31, 2008

June 1, 2009

7. (previously presented) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R<sup>3</sup> is selected from halo, nitro, C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkoxy; wherein R<sup>3</sup> may be optionally substituted on carbon by one or more R<sup>12</sup>; and R<sup>12</sup> is selected from halo.

8. (previously presented) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R<sup>5</sup> is hydrogen or optionally substituted C<sub>1-6</sub>alkyl; wherein said optional substituents are selected from one or more R<sup>14</sup>; and R<sup>14</sup> is selected from hydroxy.

9. (currently amended) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein:

R<sup>6</sup> and R<sup>7</sup> are independently selected from hydrogen, halo, nitro, cyano, amino, C<sub>1-6</sub>alkyl, N-(C<sub>1-6</sub>alkyl)amino, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, N-(C<sub>1-6</sub>alkyl)carbamoyl, C<sub>1-6</sub>alkoxycarbonyl or heterocycl; wherein R<sup>6</sup> and R<sup>7</sup> independently of each other may be optionally substituted on carbon by one or more R<sup>15</sup>; and wherein if said heterocycl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R<sup>16</sup>;

~~or R<sup>6</sup> and R<sup>7</sup> together with the pyrimidine bond to which they are attached form a 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R<sup>17</sup>; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R<sup>18</sup>;~~

R<sup>15</sup> is selected from halo, hydroxy, amino, C<sub>1-6</sub>alkoxy, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, carbocycl or heterocycl; wherein R<sup>15</sup> may be optionally substituted on carbon by one or more R<sup>19</sup>; and wherein if said heterocycl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R<sup>20</sup>;

R<sup>17</sup> is selected from halo, C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkoxy; wherein R<sup>17</sup> may be optionally substituted on carbon by one or more R<sup>19</sup>;

R<sup>18</sup> is selected from C<sub>1-6</sub>alkyl;

R<sup>19</sup> is selected from C<sub>1-6</sub>alkanoyl;

R<sup>20</sup> is selected from halo, hydroxy, C<sub>1-6</sub>alkoxy or heterocycl; and wherein if said heterocycl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R<sup>24</sup>;

Application No.  
Reply to Office Action of

10/595,807 Amendment Dated  
December 31, 2008

June 1, 2009

$R^{20}$  is selected from  $C_{1-6}$ alkyl; and

$R^{24}$  is selected from  $C_{1-6}$ alkyl.

10. (previously presented) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein  $n = 0$  or  $1$ .

11. (previously presented) A compound of formula (I) according to claim 1 wherein:

$A$  is a direct bond;

Ring  $C$  is phenyl, thienyl, pyridyl, thiazolyl;

$R^1$  is selected from hydrogen, methyl, ethyl, isopropyl, *t*-butyl, trifluoromethyl, cyclopropylmethyl, benzyl, methoxy, ethoxy, propoxy, isopropoxy, sec-butoxy, dimethylamino, methylthio or cyclopropyl;

$R^2$  is selected from methyl, ethyl, trifluoromethyl, hydroxymethyl, carboxymethyl, aminomethyl, methoxymethyl, morpholinomethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-carboxyethyl, 2-dimethylaminoethyl, 2-diethylaminoethyl, acetamidomethyl, 2-[*N*-methyl-*N*-(2-methoxyethyl)amino]ethyl, 2-[*N*-*n*ethyl-*N*-(2-hydroxyethyl)amino]ethyl, 2-(*N*-methyl(carbamoyl)ethyl, 2-[*N*-(2-hydroxyethyl)carbamoyl]ethyl, 2-(*N,N*-dimethylcarbamoyl)ethyl, 2-morpholinoethyl, 2-pyrrolidin-1-ylethyl or 2-(1-methylpiperazin-4-yl)ethyl, 1-methyl-2-hydroxyethyl;

$R^3$  is selected from fluoro, nitro, trifluoromethyl or methoxy;

$R^4$  is hydrogen;

$R^5$  is hydrogen, methyl or 2-hydroxyethyl;

$R^6$  and  $R^7$  are independently selected from hydrogen, fluoro, chloro, bromo, nitro, cyano, amino, methyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, *N*-methyl-*N*-propylamino, *N*-ethylcarbamoyl, methoxycarbonyl, ethoxycarbonyl, butoxycarbonyl, morpholino, pyrrolidinyl or piperazinyl; wherein  $R^6$  and  $R^7$  independently of each other may be optionally substituted on carbon by one or more  $R^{15}$ ; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from  $R^{16}$ ;

~~or  $R^6$  and  $R^7$  together with the pyrimidine to which they are attached form a bicyclic ring selected from quinazolinyl, thieno[3,2-*d*]pyrimidinyl, thieno[2,3-*d*]pyrimidinyl, 1H-pyrazolo[3,4-*c*]pyrimidinyl, thieno[3,4-*d*]pyrimidinyl, pyrido[2,3-*d*]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[4,3-*c*]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-*c*]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-*c*]pyrimidinyl; and wherein said bicyclic ring may be optionally substituted on carbon by one or more  $R^{17}$ ; and wherein said 5,6,7,8-tetrahydro-pyrido[4,3-*c*]pyrimidinyl, 5,6,7,8-tetrahydro-~~

Application No.  
Reply to Office Action of

10/595,807Amendment Dated  
December 31, 2008

June 1, 2009

pyrido[2,3-d]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidinyl may be optionally substituted on nitrogen by a group selected from R<sup>15</sup>;

R<sup>15</sup> is selected from fluoro, hydroxy, amino, ethoxy, dimethylamino, phenyl, pyrrolidinyl, piperazinyl or morpholino; wherein R<sup>15</sup> may be optionally substituted on carbon by one or more R<sup>16</sup>; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R<sup>20</sup>;

R<sup>16</sup> is selected from methyl;

R<sup>17</sup> is selected from fluoro, chloro, methyl, methoxy, ethoxy or propoxy; wherein R<sup>17</sup> may be optionally substituted on carbon by one or more R<sup>18</sup>;

R<sup>18</sup> is selected from acetyl;

R<sup>19</sup> is selected from fluoro, hydroxy, methoxy, piperazinyl, pyrrolidinyl or morpholino; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R<sup>24</sup>;

R<sup>20</sup> is selected from methyl;

R<sup>24</sup> is selected from methyl;

n = 0 or 1;

or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not:

5-bromo-N<sup>4</sup>-(5-methyl-1H-pyrazol-3-yl)-N<sup>2</sup>-[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-chloro-N<sup>4</sup>-(5-methyl-1H-pyrazol-3-yl)-N<sup>2</sup>-[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-bromo-N<sup>4</sup>-(5-methyl-1H-pyrazol-3-yl)-N<sup>2</sup>-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-chloro-N<sup>4</sup>-(5-methyl-1H-pyrazol-3-yl)-N<sup>2</sup>-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-chloro-N<sup>4</sup>-(5-methyl-1H-pyrazol-3-yl)-N<sup>2</sup>-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine;

5-bromo-N<sup>4</sup>-(5-methyl-1H-pyrazol-3-yl)-N<sup>2</sup>-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine; or

5-bromo-N<sup>4</sup>-(5-methyl-1H-pyrazol-3-yl)-N<sup>2</sup>-[1-(2-pyridinyl)ethyl]-2,4-pyrimidinediamine.

12. (currently amended) A compound of formula (I) selected from:

(2R)-2-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoropyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol;

5-bromo-N<sup>4</sup>-(3-cyclopropyl-1H-pyrazol-5-yl)-N<sup>2</sup>-[(1S)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine;

(2R)-2-({5-chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol;


(2R)-2-({5-chloro-4-[(3-isopropoxy-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol;

Application No.  
Reply to Office Action of10/595,807 Amendment Dated  
December 31, 2008


June 1, 2009

(3S)-3-((5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl)amino)-3-(4-fluorophenyl)-N-methylpropanamide;  
 2-((5-chloro-2-[(1S)-1-(4-fluorophenyl)ethyl]amino)-6-[(5-isopropoxy-1H-pyrazol-3-yl)amino]pyrimidin-4-yl)amino)propane-1,3-diol;  
 2-[(5-chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[(1S)-1-(4-fluorophenyl)ethyl]amino]pyrimidin-4-yl)amino]propane-1,3-diol;  
 5-chloro-N<sup>4</sup>-(5-cyclopropyl-1H-pyrazol-3-yl)-N<sup>2</sup>-[(1S)-(4-fluoro-phenyl)-ethyl]-6-(4-methylpiperazin-1-yl)-pyrimidine-2,4-diamine;  
 (2R)-2-((4-[(5-cyclopropyl-1H-pyrazol-3-yl)amine]-7-fluoroquinazolin-2-yl)amine)-2-(4-fluorophenyl)ethanol; and  
 2-[(5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino]pyrimidin-4-yl)amino]propane-1,3-diol;  
 or a pharmaceutically acceptable salt thereof.

13. (previously presented) A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in claim 1, which process comprises of  
 Process a) reaction of a pyrimidine of formula (II):



wherein L is a displaceable group; with an pyrazole amine of formula (III):




Application No.  
Reply to Office Action of10/695,807Amendment Dated  
December 31, 2008

June 1, 2009


or

Process b) reacting a pyrimidine of formula (IV):




(IV)

wherein L is a displaceable group; with a compound of formula (V):




(V)

Process c) reacting a compound of formula (VI):



(VI)

with a compound of formula (VII):




(VII)

Application No.  
Reply to Office Action of10/595,807 Amendment Dated  
December 31, 2008

June 1, 2009

wherein X is an oxygen atom and q is 1; or X is a nitrogen atom and q is 2; and wherein each R<sup>20</sup> independently represents a C<sub>1-6</sub>alkyl group; or

Process d) reacting a compound of formula (VIII):



with hydrazine; or

and thereafter if necessary:

- i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt.

14-17. (cancelled)

18. (previously presented) A method of inhibiting Trk activity comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1.

19. (previously presented) A method for the treatment or prophylaxis of cancer comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in claim 1.

20. (previously presented) A method of producing an anti-proliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1.

Application No.  
Reply to Office Action of

10/595,807Amendment Dated  
December 31, 2008

June 1, 2009

21. (previously presented) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, together with at least one pharmaceutically acceptable carrier, diluent or excipient.

22-27. (cancelled)

28. (previously presented) The method according to claim 19 wherein said cancer is selected from oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, kaposi's sarcoma, ovarian cancer; breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma, leukaemia, tumours of the central and peripheral nervous system, melanoma, fibrosarcoma and osteosarcoma.